

June 28, 2019

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Sub: Disclosure of Related Party Transactions under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards.

The said disclosure has also been published on the website of the Company. Kindly consider same in your records.

Thanking you.

Yours faithfully,  
For Glenmark Pharmaceuticals Limited



Harish Kuber  
Company Secretary Compliance Officer

Encl: As above

Information on significant related party transactions on a consolidated basis as required by Ind AS-24 - 'Related Party Disclosures' are given below:

**Related parties with whom the Group has transacted during the year**

**Key Management Personnel**

Mr. Glenn Saldanha (Chairman & Managing Director)

Mrs. Cherylann Pinto (Executive Director)

Mr. V S Mani (President & Global Chief Financial Officer till May 29, 2018, Executive Director & Global Chief Financial Officer from May 29, 2018)

Mr. Rajesh Desai (Non-executive Director)

Mr. Murali Neelakantan (Executive Director till May 29, 2018)

Mr. Harish Kuber (Company Secretary & Compliance Officer)

Mrs. B. E. Saldanha (Non-executive Director)

Mr. D.R.Mehta (Non-executive Director)

Mr. Bernard Munos (Non-executive Director)

Mr. J.F.Ribeiro (Non-executive Director)

Dr.Brian W. Tempest (Non-executive Director)

Mr. Sridhar Gorthi (Non-executive Director)

Mr. Milind Sarwate (Non-executive Director)

Ms. Ruchita Gandhi (CFO of subsidiary with effect from January 1, 2019)

**Enterprises over which significant influence exercised by key management personnel/directors**

Glenmark Foundation

Glenmark Aquatic Foundation

Trilegal

Nature of Transaction	Rs in million
	Year ended 31 March 2019
<b>Purchase of services</b>	
Trilegal	24.59
<b>Expenditure incurred for CSR activities to</b>	
Glenmark Foundation	141.76
Glenmark Aquatic Foundation	64.00
<b>Transactions with key management personnel</b>	
Remuneration	
- Mr. Glenn Saldanha	157.05
- Mrs. Cherylann Pinto	42.92
- Mr V S Mani	45.6
- Mr Murali Neelakantan (Related party as per companies Act,2013 till May 29, 2018)	43.07
- Mr. Harish Kuber	3.27
- Ms. Ruchita Gandhi (Related party as per companies Act,2013 with effect from January 1, 2019)	1.66
Sitting fees paid to Non-executive Directors	8.3
<b>Related party balances</b>	<b>As at 31 March 2019</b>
	<b>Rs in million</b>
(Payable)/ Advance given	
Glenmark Foundation	(1.00)

The directors are covered under the Group's gratuity policy and ESOP scheme along with other employees of the Group. Proportionate amount of gratuity and stock compensation expense is not included in the aforementioned disclosures as it cannot be separately ascertained.

